semaglutide flow Brendon Neuen on X: "Johannes Mann ending with a plug for the trial, the only dedicated renal outcome trial testing the effect of GLP1-RA ( semaglutide) on a primary outcome of 50% FLOWing with the SemagluTIDE —

They reduce appetite in a sustainable way : Instead of forcing restriction, these peptides help your brain better understand when youve had enough to eat

These chemically altered fats were designed to last longer, improve texture, and increase shelf life

Additionally, evidence-based strategies help prevent weight regain, ensuring patients maintain results and continue progressing toward improved metabolic health

Short half-life agents (exenatide twice daily or lixisenatide) produce spikes with transient increases in plasma arGLP-1 levels, resulting in intermittent activation of the receptor and have a potent effect on gastric emptying and postprandial glycemia by reducing the rate of glucose entry into the duodenum